Abstract P1063: Association of Demographic and Clinical Factors with SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study
Abstract
Background: Despite the availability of effective vaccines and a recent decrease in annual deaths, coronavirus disease-2019 (COVID-19) remains a leading cause of death. Serological studies of anti-nucleocapsid (N) antibody response to infection provide insights into host immunobiology of adaptive immune response, which holds promise for identifying high-risk individuals for adverse acute and chronic COVID-19 outcomes. Hypothesis: Among participants previously infected with SARS-CoV-2, traditional vascular disease risk factors are associated with higher anti-N antibodies while vaccination is associated with lower anti-N antibodies. Methods: Among previously infected participants, anti-N antibodies were measured from dried blood spots collected between February 2021-February 2023 among 1,419 Collaborative Cohort of Cohorts for COVID-19 Research (C4R) participants with prior SARS-CoV-2 infection. We measured anti-N IgG antibodies reported as median fluorescence intensity (MFI) units; reactivity (i.e., seropositivity) was defined based on MFI above a validated threshold. Vascular disease risk factors were assessed via pre-pandemic in-person examination, questionnaires, and medical record review. Multivariable generalized linear models regressed anti-N reactivity (modified Poisson) or LN transformed MFI (linear). Results: Among 1,419 participants with prior infection, mean age (standard deviation) was 65.8(12.1) years, 61% were women, and 42.8% were self-reported from a race/ethnicity minority group. Participant reactivity to nucleocapsid peaked at 69% by 4 months post-infection and waned to only 44% ≥12 months after infection. After multivariable adjustment, higher anti-N antibody response was associated with older age, Hispanic (vs. White) or American Indian (vs. White) race/ethnicity, lower income and education, former smoking, and higher anti-spike antibody levels. Asian race (vs. White) and vaccination ( even after infection ) were associated with lower nucleocapsid reactivity; common cardiometabolic co-morbidities were not associated with anti-N reactivity or levels (Figures 1 and 2). Conclusions: Among participants previously infected with SARS-CoV-2, select sociodemographic and behavioral risk factors were associated with higher anti-N antibody levels while vaccination was associated with lower anti-N antibody levels. The observation that vaccination, even after infection, is related to lower anti-N antibody levels merits further investigation.
Article Details
Authors (37)
Ryan Demmer
Mayo Clinic, Rochester, Minnesota, United States
Chaoqi Wu
Columbia University, New York City, New York, United States
John Kim
Yifei Sun
State Key Laboratory of Green Pesticide, Engineering Research Center of Photoenergy Utilization for Pollution Control and Carbon Reduction, Ministry of Education, College of Chemistry
Pallavi Balte
Mary Cushman
Rebekah Boyle
University of Vermont, Burlington, Vermont, United States
Russell Tracy
Linda Styer
New York State Department of Health, Albany, New York, United States
Taison Bell
UVA Health, Charlottesville, Virginia, United States
Michaela Anderson
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Norrina Allen
NORTHWESTERN UNIVERSITY, Chicago, Illinois, United States
Pamela Schreiner
UNIV MINNESOTA, Minneapolis, Minnesota, United States
Russell Bowler
David Schwartz
University of Colorado, Aurora, Colorado, United States
Joyce Lee
Bionano Genomics Inc
Vanessa Xanthakis
Jean Rock
New York State Department of Health, Albany, New York, United States
Rachel Bievenue
Amber Pirzada
Margaret Doyle
University of Vermont, Burlington, Vermont, United States
Elizabeth Regan
National Jewish Health, Denver, CO, USA.
Barry Make
Johns Hopkins University, Baltimore, MD, USA.
Alka Kanaya
UCSF, San Francisco, California, United States
Namratha Kandula
Northwestern University, Chicago, Illinois, United States
S Morganroth
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Joe Coresh
New York University Grossman School of Medicine, New York, New York, United States
Carmen Isasi
Albert Einstein College of Medicine, Bronx, New York, United States
Laura Raffield
Mitchell Elkind
American Heart Association, Dallas, Texas, United States
Virginia Howard
University of Alabama at Birmingham, Birmingham, Alabama, United States
Victor Ortega
Mayo Clinic, Carefree, Arizona, United States
Prescott Woodruff
Shelley Cole
Texas Biomedical Research Institute, San Antonio, Texas, United States
Joel Henderson
Nicholas Mantis
New York State Department of Health, Albany, New York, United States
Elizabeth Oelsner
Columbia University, New York, New York, United States